Weave Bio provides an AI-native regulatory platform designed to streamline the preparation and management of complex therapeutic dossiers. The platform accelerates data organization, authoring, review, and publishing using eCTD-formatted templates, enabling faster and more accurate submissions. It facilitates real-time team collaboration and content generation, allowing regulatory professionals to direct strategy rather than manually compile documentation.
Funding
$10.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+2Founders
Product
Problem
Preparing Investigational New Drug (IND) submissions is a time-consuming process, often taking months to draft and finalize due to the manual organization of data and document generation. This lengthy process delays the submission, diverting biomedicine teams from strategic planning and decision-making.
Solution
Weave provides an AI-powered platform designed to streamline the creation and quality control of IND submissions. The platform automates data organization, document drafting, and updating, significantly reducing the time required for IND preparation. By leveraging AI, Weave enables teams to efficiently navigate data, generate drafts rapidly, and maintain adherence to regulatory guidelines. This allows teams to focus on strategic planning and creative thinking, accelerating the IND submission process without compromising quality.
Target Audience
The primary target audience includes biomedicine teams and pharmaceutical companies involved in the preparation and submission of Investigational New Drug (IND) applications.
Features
- AI-powered document drafting that generates initial drafts within minutes.
- Automated organization of content with tagging and search capabilities.
- AI-driven summaries and rapid tracing of content to source documents.
- Streamlined quality control and review process with automated updates.
- Conflict resolution tools for IND data discrepancies.
- Reporting on affected sections post-update.
- Collaborative features for multiple reviewers.